Use of selective β3 and PPARγ agonists for metabolic staging of insulin responsive target tissues both in vivo and in vitro

Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.

Facebook Linkedin Weibo

PDF herunterladen

Exp Clin Endocrinol Diabetes 1997; 105: 73-74
DOI: 10.1055/s-0029-1211898

Session 8: Therapeutic approach and pharmacological considerations for the treatment of spontaneous IDDM and NIDDM

K. K. Brown^* , W. H. Harrington^* , B. W. Wiard^* , S. Collins⁺ , M. Paulik^* , J. Lenhard^*

^* Glaxo Wellcome Research Institute, Moore Dr., Research Triangle Park, NC, USA
⁺ Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

Weitere Informationen

Publikationsdatum:
15. Juli 2009 (online)